Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies
Giorgia Teresa Maniscalco, Antonietta Liotti, Anne Lise Ferrara, Elio Prestipino, Simona Salvatore, Maria Elena Di Battista, Ornella Moreggia, Daniele Di Giulio Cesare, Roberta Vastano, Martina Belardo, Massimo Napolitano, Angelo Ranieri, Katia Longo, Vincenzo Andreone, Veronica De Rosa
Topics & Concepts
MedicineFingolimodMultiple sclerosisImmunologyImmune systemSeroconversionTeriflunomideVaccinationDimethyl fumarateCladribineOcrelizumabBooster doseInternal medicineAntibodyRituximabImmunizationSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesLong-Term Effects of COVID-19